CompletedNot Applicable

Toxicity Outcomes of Simultaneous Integrated Boost in Adjuvant Breast Radiotherapy Acronym

Slovenia93 participantsStarted 2019-01-01

Plain-language summary

This prospective study systematically evaluates toxicity outcomes in breast cancer patients treated with adjuvant radiotherapy using the simultaneous integrated boost (SIB) technique after breast-conserving surgery. The aim is to monitor acute and late treatment-related side effects during implementation of this radiotherapy approach and to compare institutional toxicity outcomes with published data in the literature.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female patients with histologically confirmed breast cancer * Status post breast-conserving surgery (lumpectomy) * Planned adjuvant whole-breast radiotherapy with simultaneous integrated boost (SIB) to the tumor bed * Age ≥ 18 years * Ability to provide informed consent Exclusion Criteria: * Prior radiotherapy to the breast or thoracic region * Mastectomy (no breast-conserving surgery) * Pregnancy or breastfeeding * Inability to complete planned radiotherapy or follow-up assessments

What they're measuring

Acute Radiation Toxicity (CTCAE)

Timeframe: From start of radiotherapy up to 3 months after completion of radiotherapy

Acute Radiation Toxicity (CTCAE)

Timeframe: From start of radiotherapy up to 3 months after completion of radiotherapy

Trial details

NCT IDNCT07407192

SponsorInstitute of Oncology Ljubljana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Breast Cancer trials